Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889

Effectiveness of COVID-19 vaccines against the B.1.617.2 variant

Bernal, J. L., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · doi:10.1101/2021.05.22.21257658 · Cited by 2,888

Evolution of antibody immunity to SARS-CoV-2

Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Voysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00432-3 · Cited by 1,119

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.

Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01358-1 · Cited by 939

Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

(2021) · doi:10.1101/2021.06.01.21258172 · Cited by 425

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Barros-Martins, J., Hammerschmidt, S. I., Cossmann, A., Odak, I., Stankov, M. V., Morillas Ramos, G., Dopfer-Jablonka, A., Heidemann, A., Ritter, C., Friedrichsen, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01449-9 · Cited by 425

Factors Affecting SARS-CoV-2 IgG Production after Vaccination and/or Disease: A Large-Scale Seroprevalence Study

Karl, T., Schuster, A., Stangassinger, L. M., Stiboller, T., Cadamuro, J., & Oostingh, G. J. (2023) · Vaccines · doi:10.3390/vaccines11101615 · Cited by 7

Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice

Cervantes‐Torres, J. B., Cabello-Gutiérrez, C., Ayón‐Núñez, D. A., Soldevila, G., Olguín‐Alor, R., Díaz, G., Acero, G., Segura‐Velázquez, R. A., Huerta, L., Gracia‐Mora, I., et al. (2024) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-023-12927-0 · Cited by 7

COVID-19 herd immunity v. learning to live with the virus

Madhi, S. A. (2021) · South African Medical Journal · doi:10.7196/samj.2021.v111i9.16005 · Cited by 7

Delayed Humoral Response After 2 Doses of the BNT162b2 Vaccine in a Belgian Kidney Transplant Cohort

Georgery, H., Devresse, A., Albichr, I. S., Lucas, S., Yombi, J. C., Belkhir, L., Greef, J. D., Scohy, A., Kabamba, B., Goffin, E. J., et al. (2021) · Transplantation · doi:10.1097/tp.0000000000003952 · Cited by 8

Seroprevalence of SARS-CoV-2 antibodies among blood donors in Québec: an update from a serial cross-sectional study

Lewin, A., Serres, G. D., Grégoire, Y., Perreault, J., Drouin, M., Fournier, M., Tremblay, T., Beaudoin, J., Boivin, A., Goyette, G., et al. (2022) · Canadian Journal of Public Health · doi:10.17269/s41997-022-00622-y · Cited by 8

Combating COVID-19 crisis and exploring heat-based simple solutions

Roy, I. (2022) · Physics and Chemistry of the Earth Parts A/B/C · doi:10.1016/j.pce.2022.103333 · Cited by 8

Comparative effectiveness of different primary vaccination courses on mRNA-based booster vaccines against SARs-COV-2 infections: a time-varying cohort analysis using trial emulation in the Virus Watch community cohort

Nguyen, V. G., Yavlinsky, A., Beale, S., Hoskins, S., Byrne, T., Lampos, V., Braithwaite, I., Fong, W. L. E., Fragaszy, E., Geismar, C., et al. (2023) · International Journal of Epidemiology · doi:10.1093/ije/dyad002 · Cited by 8

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity

Kim, J. N., Kim, C., Lee, J. A., Lee, S. J., Lee, K. H., Kim, J. H., Ahn, J. Y., Jeong, S. J., Ku, N. S., Yeom, J., et al. (2023) · Vaccines · doi:10.3390/vaccines11040784 · Cited by 8

Impact of vaccine measures on the transmission dynamics of COVID-19

Liu, H., Han, X., Lin, X., Zhu, X., & Wei, Y. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290640 · Cited by 8

A third COVID-19 vaccine shot markedly boosts neutralizing antibody potency and breadthPreprint

Iketani, S., Liu, L., Nair, M. S., Mohri, H., Wang, M., Huang, Y., & Ho, D. D. (2021) · medRxiv · doi:10.1101/2021.08.11.21261670 · Cited by 8

Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study

Nelli, F., Fabbri, A., Panichi, V., Giannarelli, D., Topini, G., Berrìos, J. R. G., Virtuoso, A., Marrucci, E., Mazzotta, M., Schirripa, M., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108774 · Cited by 7

Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination

Parés‐Badell, O., Zules-Oña, R., Armadans, L., Pinós, L., Borràs-Bermejo, B., Otero‐Romero, S., Rodrigo‐Pendás, J. Á., Vivet-Escalé, M., Cossio‐Gil, Y., Agustí, A., et al. (2022) · Vaccines · doi:10.3390/vaccines10081217 · Cited by 7

Comparison of the rapidity of SARS-CoV-2 immune responses between primary and booster vaccination for COVID-19

Kim, J. Y., Kwon, J., Cha, H. H., Lim, S. Y., Bae, S., & Kim, S. (2022) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2022.173 · Cited by 7

A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern

Lee, I., Lan, Y.-H., Wu, P., Wu, Y., Chen, Y.-H., Tseng, S.-C., Kuo, T.-J., Sun, C., Jan, J., Ma, H., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2149353 · Cited by 8

Post-vaccination seropositivity against SARS-CoV-2 in peruvian health workers vaccinated with BBIBP-CorV (Sinopharm)

Cvetković-Vega, A., Urrunaga‐Pastor, D., Soto-Becerra, P., Figueroa-Montes, L. E., Bolívar, L. F., Alvizuri-Pastor, S. E., Oyanguren-Miranda, M., Vera, I. M. N., Carrillo-Ramos, E., Soto, A. A. I. S., et al. (2022) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2022.102514 · Cited by 8

Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2

Jung, H. E., Ku, K. B., Kang, B. H., Park, J. H., Kim, H. C., Kim, K., & Lee, H. K. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105656 · Cited by 9

Persistence of SARS-CoV-2 Antibodies in Vaccinated Health Care Workers Analyzed by Coronavirus Antigen Microarray

Hosseinian, S., Powers, K., Vasudev, M., Palma, A. M., de Assis, R., Jain, A., Horvath, P., Birring, P. S., Andary, R., Au, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.817345 · Cited by 7

Advances in COVID-19 Vaccines and New Coronavirus Variants

Liu, M., & Li, Y. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.888631 · Cited by 7

Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants

Moghnieh, R., Hajj, C. E., Abdallah, D., Jbeily, N., Bizri, A. R., & Sayegh, M. H. (2022) · Vaccines · doi:10.3390/vaccines10101596 · Cited by 8

Dynamic Antibody Response in SARS-CoV-2 Infected Patients and COVID-19 Vaccine Recipients, and Vaccine Effectiveness in Comorbid and Multimorbid Patients

Das, D., Raha, F. K., Adnan, K. M., Siraj, M. R., Shapla, M. J., Shumy, F., Haque, M. E., Khan, M. H., Sanyal, S., Hosen, M. I., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2023.e16349 · Cited by 7

Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison

Kroidl, I., Winter, S., Rubio‐Acero, R., Bakuli, A., Geldmacher, C., Eser, T. M., Deák, F., Horn, S., Zielke, A., Ahmed, M. I. M., et al. (2023) · Virology Journal · doi:10.1186/s12985-023-02167-z · Cited by 7

Effect of booster vaccination against Delta and Omicron SARS-CoV-2 variants in Iceland

Norddahl, G. L., Melsted, P., Gunnarsdóttir, K., Halldorsson, G. H., Olafsdottir, T. A., Gylfason, A., Kristjánsson, M., Magnússon, Ó. Þ., Sulem, P., Gudbjartsson, D. F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33076-4 · Cited by 7

Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses

Ahmed‐Belkacem, A., Redjoul, R., Brillet, R., Ahnou, N., Leclerc, M., Molina, D. S. L., Soulier, A., Gourgeon, A., Rodriguez, C., Maury, S., et al. (2022) · Viruses · doi:10.3390/v14091928 · Cited by 6

Plasma EV-miRNAs as Potential Biomarkers of COVID-19 Vaccine Immune Response in Cancer Patients

Almeida, B., Dias, T. R., Cruz, P., Sousa‐Pimenta, M., Teixeira, A. L., Pereira, C. E., Costa‐Silva, B., Oliveira, J., Medeiros, R., & Dias, F. (2024) · Vaccines · doi:10.3390/vaccines12080848 · Cited by 6

Co-immunization with spike and nucleocapsid based DNA vaccines for long-term protective immunity against SARS-CoV-2 Omicron

Pinto, P. B. A., Timis, J., Chuensirikulchai, K., Li, Q. H., Lu, H.-H., Maule, E., Nguyen, M. N., Alves, R. P. D. S., Verma, S. K., Ana‐Sosa‐Batiz, F., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-01043-3 · Cited by 8

Barrier Gesture Relaxation during Vaccination Campaign in France: Modelling Impact of Waning Immunity

Vignals, C., Dick, D. W., Thiébaut, R., Wittkop, L., Prague, M., & Heffernan, J. M. (2021) · COVID · doi:10.3390/covid1020041 · Cited by 6

Biology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the humoral immunoresponse: a systematic review of evidence to support global policy-level actions and research

Nair, S., & Chen, X. (2021) · Global Health Journal · doi:10.1016/j.glohj.2021.11.005 · Cited by 6

BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19

Kaznadzey, A., Tutukina, M. N., Bessonova, T. A., Kireeva, M. L., & Mazo, I. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.797918 · Cited by 6

Hospitalised patients with breakthrough COVID-19 following vaccination during two distinct waves in Israel, January to August 2021: a multicentre comparative cohort study

Brosh‐Nissimov, T., Maor‬‏, ‪., Elbaz, M., Lipman‐Arens, S., Weil‐Weiner, Y., Hussein, K., Orenbuch‐Harroch, E., Cohen, R., Zimhony, O., Chazan, B., et al. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.20.2101026 · Cited by 7

Knowledge, perception, and acceptance toward the booster dose of COVID-19 vaccine among patients visiting dental clinics in Aseer region of KSA

Abullais, S. S., Arora, S., Alshahrani, M. S., Khan, A. A., Shahrani, W. A., Mahmood, S. E., Qahtani, S. A., Maqbool, M., Jameel, A. S., & Saluja, P. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2095162 · Cited by 6

Comparative Characterization of Human Antibody Response Induced by BNT162b2 Vaccination vs. SARS-CoV-2 Wild-Type Infection

Lagousi, T., Routsias, J. G., Mavrouli, M. D., Papadatou, I., Geropeppa, M., & Spoulou, V. I. (2022) · Vaccines · doi:10.3390/vaccines10081210 · Cited by 6

Dynamic Analysis of a VSEIR Model with Vaccination Efficacy and Immune Decline

Han, X., Liu, H., Lin, X., Wei, Y., & Ma, M. (2022) · Advances in Mathematical Physics · doi:10.1155/2022/7596164 · Cited by 6

Effectiveness of COVID-19 Vaccination In Healthcare Workers in Shiga Prefecture, Japan

Chano, T., Yamashita, T., Fujimura, H., Kita, H., Ikemoto, T., Kume, S., Morita, S., Suzuki, T., & Kakuno, F. (2022) · Scientific Reports · doi:10.1038/s41598-022-22682-3 · Cited by 6

Postexposure‐vaccine‐prophylaxis against COVID‐19

Shmuelian, Z., Warszawer, Y., Or, O., Arbel‐Alon, S., Giladi, H., Tsadok, M. A., Cohen, R., Shefer, G., Shlomi, D., Hoshen, M. B., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28274 · Cited by 6

Waning of Humoral Immunity and the Influencing Factors after BNT162b2 Vaccination: A Cohort Study with a Latent Growth Curve Model in Fukushima

Kobashi, Y., Takebayashi, Y., Yoshida, M., Kawamura, T., Shimazu, Y., Kaneko, Y., Nishikawa, Y., Nakayama, A., Takita, M., Zhao, T., et al. (2022) · Vaccines · doi:10.3390/vaccines10122007 · Cited by 5

Immunogenicity of BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 nCoV-19 Vaccines Six Months after the Second Dose: A Longitudinal Prospective Study

Petrović, V., Vuković, V., Patić, A., Marković, M., & Ristić, M. (2022) · Vaccines · doi:10.3390/vaccines11010056 · Cited by 6

Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand

Phumisantiphong, U., Chunhakan, S., Manomaipiboon, A., Maneerit, J., Dechanuwong, P., Trakarnvanich, T., Oajaum, W., & Chan-in, W. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100277 · Cited by 6

Immunogenicity, effectiveness and safety of COVID-19 vaccine in older adults living in nursing homes: A real-life study

Míguez, H. M., García, I. M., Gómez, M. O., Merino, I. M. G., Cano, E. L., & de la Torre, A. (2023) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2023.02.009 · Cited by 6

Post COVID-19 vaccination binding and neutralizing antibody with or without previous infection: An 18-month longitudinal study in Indonesia

Ardyanto, T. D., Khariri, K., Agus, T. P., & Subandrio, A. (2024) · Narra J · doi:10.52225/narra.v4i2.1071 · Cited by 7

Evaluación de la respuesta de los anticuerpos IGG específicos contra SARS-CoV-2 en el personal de salud con el esquema completo de la vacuna Sputnik V (Gam-COVID-Vac)

Córdova, E., Lespada, M. I., Cecchini, D. M., Nieto, F., Palonsky, S., Badran, M., Bernasconi, S. V., Bacelar, B., Morganti, L., Garibaldi, F., et al. (2022) · Vacunas · doi:10.1016/j.vacun.2022.01.008 · Cited by 6

Effect of the incremental protection of previous infection against Omicron infection among individuals with a hybrid of infection- and vaccine-induced immunity: a population-based cohort study in Canada

Wu, S., Li, Y., Mishra, S., Bodner, K., Baral, S., Kwong, J. C., & Wei, X. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.11.028 · Cited by 6

A single dose ChAdOx1 nCoV-19 vaccine elicits high antibody responses in individuals with prior SARS-CoV-2 infection comparable to that of double dose vaccinated SARS-CoV-2 infection naïve individualsPreprint

Gelanew, T. I., Mulu, A., Abebe, M., Bates, T. A., Wassie, L., Tefer, M., Fentahun, D., Alemu, A., Tamiru, F., Assefa, G., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1250175/v1 · Cited by 6

Dynamics of SARS-CoV-2 Seroprevalence in a Large US population Over a Period of 12 MonthsPreprint

Karkanitsa, M. L., Li, Y., Valenti, S., Spathies, J., Kelly, S., Hunsberger, S., Yee, L. M., Croker, J. A., Wang, J., Alfonso, A. L., et al. (2023) · medRxiv · doi:10.1101/2023.10.20.23297329 · Cited by 5

The Third Booster Vaccination Dose Against COVID-19: Indications for Circulating SARS-CoV-2 Variants

Rahimi, F., & Abadi, A. T. B. (2021) · Future Virology · doi:10.2217/fvl-2021-0240 · Cited by 5

Profound decline of antibody titers 6 months after BNT162b2 vaccination in healthy volunteers

Kozakai, R., Hoshi, K., Izumi, Y., & Takahashi, S. (2021) · Journal of Laboratory Medicine · doi:10.1515/labmed-2021-0147 · Cited by 5

Long‐term effects of homologous and heterologous SARS‐CoV ‐2 vaccination on humoral and cellular immune responses

Hollstein, M. M., Münsterkötter, L., Schön, M. P., Bergmann, A., Husar, T. M., Abratis, A., Eidizadeh, A., Dierks, S., Schaffrinski, M., Zachmann, K., et al. (2022) · Allergy · doi:10.1111/all.15373 · Cited by 5

SARS-CoV-2 RBD-Specific Antibodies Induced Early in the Pandemic by Natural Infection and Vaccination Display Cross-Variant Binding and Inhibition

Walker, M. R., Podlekareva, D. N., Johnsen, S., Leerhøy, B., Fougeroux, C. E., Søgaard, M., Salanti, A., Ditlev, S. B., & Barfod, L. K. (2022) · Viruses · doi:10.3390/v14091861 · Cited by 5

Impacts of delta and omicron variants on inactivated SARS‐CoV‐2 vaccine‐induced T cell responses in patients with autoimmune diseases and healthy controls

Wang, S., Li, J., Wang, S., Ye, Y., Li, M., Liu, Y., Chen, B., Lai, Y., Li, L., Zhuang, L., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1171 · Cited by 5

Dynamics of SARS-CoV-2 Spike-IgG throughout Three COVID-19 Vaccination Regimens: A 21-Month Longitudinal Study of 82 Norwegian Healthcare Workers

Augustinussen, M. H., Tylden, G. D., & Rinaldo, C. H. (2023) · Viruses · doi:10.3390/v15030619 · Cited by 7

Seasonality, mass vaccination and critical policy evaluation on global exit strategy of COVID-19 crisis

Roy, I., Chapungu, L., & Nyambiya, I. (2023) · Physics and Chemistry of the Earth Parts A/B/C · doi:10.1016/j.pce.2023.103388 · Cited by 5

Comparison of self-reported symptoms in COVID-19 patients who had or had not previously received COVID-19 mRNA vaccination

Hara, M., Furue, T., Fukuoka, M., Iwanaga, K., Matsuishi, E., Miike, T., Sakamoto, Y., Mukai, N., Kinugasa, Y., Shigyo, M., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2226575 · Cited by 5

Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study

Hou, C., Williams, S. A., Taylor, K., Boyle, V., Bobbett, B., Kouvetakis, J., Nguyen, K., McDonald, A., Harris, V. K., Nussle, B., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-072627 · Cited by 4

COVID-19 Infection despite Previous Vaccination in Cancer Patients and Healthcare Workers: Results from a French Prospective Multicenter Cohort (PAPESCO-19)

Seegers, V., Rousseau, G., Zhou, K., Blanc-Lapierre, A., Bigot, F., Mahammedi, H., Lambert, A., Moreau-Bachelard, C., Campone, M., Conroy, T., et al. (2023) · Cancers · doi:10.3390/cancers15194777 · Cited by 5

BNT162b2 Booster Dose Elicits a Robust Antibody Response in Subjects with Abdominal Obesity and Previous SARS-CoV-2 Infection

Malavazos, A. E., Dubini, C., Milani, V., Boveri, S., Meregalli, C., Bertolini, C., Buscemi, C., Cardani, R., Renna, L. V., Trevisan, M. B., et al. (2023) · Vaccines · doi:10.3390/vaccines11121796 · Cited by 6

Risk Factors and Incidence Rates of Covid-19 Breakthrough Infections in Vaccinated People in General Medicine Practice in Toledo (Spain)

Luis, T. J. (2022) · Archives of Family Medicine and General Practice · doi:10.36959/577/505 · Cited by 5

Humoral and cellular immune responses against SARS-CoV-2 variants of concern induced by heterologous CoronaVac/ChAdOx-1 versus homologous ChAdOx-1 vaccination in the elderly

Liwsrisakun, C., Pata, S., Laopajon, W., Takheaw, N., Chaiwong, W., Duangjit, P., Inchai, J., Chuensirikulchai, K., Cheyasawan, P., Pothirat, C., et al. (2023) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-120822-1434 · Cited by 5

Immunogenicity and real-world effectiveness of COVID-19 vaccines in Lebanon: Insights from primary and booster schemes, variants, infections, and hospitalization

Moghnieh, R., Haddad, W., Jbeily, N., El-Hassan, S., Eid, S., Baba, H., Sily, M., Saber, Y., Abdallah, D., Bizri, A. R., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306457 · Cited by 5

Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It

Yan, Z., Yang, M., & Lai, C. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.858006 · Cited by 4

Impact of COVID-19 on Mucosal Immunity and Antibody Responses in COVID Vaccinees

Kannian, P., Eniya, M. L., Mahanathi, P., Gracemary, A., Kumarasamy, N., & Challacombe, S. (2025) · Vaccines · doi:10.3390/vaccines13090967 · Cited by 4

Serological Response to COVID-19 Vaccination in Saudi Arabia: A Comparative Study of IgG and Neutralising Antibodies Across Vaccine Platforms

AlEissa, M. M., Alsaieedi, A., Alduaiji, R., Almsned, F. M., Aldossary, Y. M., Saleh, N. M., AlQurashi, R. A., Hawsa, E. A., shaded, M. B., Alshehri, A. M., et al. (2025) · Vaccines · doi:10.3390/vaccines13101042 · Cited by 4

Anti-RBD Antibody Levels and IFN-γ-Specific T Cell Response Are Associated with a More Rapid Swab Reversion in Patients with Multiple Sclerosis after the Booster Dose of COVID-19 Vaccination

Aiello, A., Ruggieri, S., Navarra, A., Tortorella, C., Vanini, V., Haggiag, S., Prosperini, L., Cuzzi, G., Salmi, A., Quartuccio, M. E., et al. (2024) · Vaccines · doi:10.3390/vaccines12080926 · Cited by 4

Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA

Schmiedeberg, K., Abela, I. A., Pikor, N. B., Vuilleumier, N., Schwarzmüller, M., Epp, S., Pagano, S., Grabherr, S., Patterson, A. B., Nussberger, M., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002575 · Cited by 5

Mix-and-match COVID-19 vaccines trigger high antibody response after the third dose vaccine in Moroccan health care workers

Amellal, H., Assaid, N., Akarid, K., Maaroufi, A., Ezzikouri, S., & Sarih, M. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100288 · Cited by 5

Evaluation of Antibody Kinetics Following COVID-19 Vaccination in Greek SARS-CoV-2 Infected and Naïve Healthcare Workers

Pavlidis, G., Giannoulis, V., Pirounaki, M., Lampropoulos, I. C., Siafi, E. P., Nitsa, A., Pavlou, E. G., Xanthaki, A., Perlepe, G., Fortis, S. P., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13060910 · Cited by 4

Humoral and cellular immune responses in fully vaccinated individuals with or without SARS‐CoV‐2 breakthrough infection: Results from the CoV‐ADAPT cohort

Hollstein, M. M., Dierks, S., Schön, M. P., Bergmann, A., Abratis, A., Eidizadeh, A., Kaltenbach, S., Schanz, J., Groß, U., Leha, A., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29122 · Cited by 4

Safety and efficacy of SARS‐CoV ‐2 vaccination in patients with immune thrombocytopenia: A two‐centre review

Stefani, S. D., Buti, N., Hart, A. C. J., Paul, D., Rizvi, N., Ragoonanan, V., Vladescu, C., Szydlo, R., Ademokun, C., Jansen, A. J. G., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.19212 · Cited by 4

Determinants of Systemic SARS-CoV-2-Specific Antibody Responses to Infection and to Vaccination: A Secondary Analysis of Randomised Controlled Trial Data

Claus, J., ten Doesschate, T., Taks, E., Debisarun, P. A., Smits, G. P., van Binnendijk, R. S., van der Klis, F. R. M., Verhagen, L. M., de Jonge, M. I., Bonten, M. J. M., et al. (2024) · Vaccines · doi:10.3390/vaccines12060691 · Cited by 4

A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variants

Metzdorf, K., Jacobsen, H., 김연수, Alves, L. G. T., Kulkarni, U., Eschke, K., Chaudhry, M. Z., Hoffmann, M., Bertoglio, F., Ruschig, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1383086 · Cited by 4

mRNA or ChAd0x1 COVID-19 Vaccination of Adolescents Induces Robust Antibody and Cellular Responses With Continued Recognition of Omicron Following mRNA-1273

Dowell, A. C., Powell, A. A., Davis, C., Scott, S., Logan, N. A., Willett, B. J., Bruton, R. K., Ayodele, M., Jinks, E., Gunn, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.882515 · Cited by 5

Determinants of seropositivity for SARS-CoV-2 in hospital staff in the second wave of the pandemic in Slovenia

Sočan, M., Prosenc, K., Kukec, A., Zaletel‐Kragelj, L., Remec, T., & Grmek-Košnik, I. (2022) · International Journal of Occupational Medicine and Environmental Health · doi:10.13075/ijomeh.1896.01932 · Cited by 4

Protection from successive Omicron variants with SARS-CoV-2 vaccine and monoclonal antibodies in kidney transplant recipients

Moal, V., Valade, M., Boschi, C., Robert, T., Orain, N., Bancod, A., Edouard, S., Colson, P., & Scola, B. L. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1147455 · Cited by 4

The Effect of COVID-19 Vaccines on Hospital Admission and Severity of Symptoms Among COVID-19 Patients in Saudi Arabia, 2021

Alnemari, R. F., Roublah, F. A., & Bargawi, A. A. (2023) · Cureus · doi:10.7759/cureus.41067 · Cited by 6

High Levels of Anti-SARS-CoV-2 Receptor-Binding Domain (RBD) Antibodies One Year Post Booster Vaccinations among Hospital Workers in Indonesia: Was the Second Booster Needed?

Muslimah, A. H., Tiara, M. R., Djauhari, H., Dewantara, M. H. A., Susandi, E., Indrati, A. R., Alisjahbana, B., Soeroto, A. Y., & Wisaksana, R. (2023) · Vaccines · doi:10.3390/vaccines11081300 · Cited by 4

Seroprevalence of SARS-CoV-2 in a Large Cohort of Italian Police Officers

Garbarino, S., Domnich, A., Costa, E., Giberti, I., Mosca, S., Belfiore, C., Ciprani, F., & Icardi, G. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182212201 · Cited by 6

Selection and T-cell antigenicity of synthetic long peptides derived from SARS-CoV-2

Piadel, K., Haybatollahi, A., Dalgleish, A. G., & Smith, P. L. (2022) · Journal of General Virology · doi:10.1099/jgv.0.001698 · Cited by 4

Humoral response after a BNT162b2 heterologous third dose of COVID-19 vaccine following two doses of BBIBP-CorV among healthcare personnel in Peru

Montero, S., Urrunaga‐Pastor, D., Soto-Becerra, P., Cvetković-Vega, A., Guillermo-Roman, M., Figueroa-Montes, L. E., Soto, A. A. I. S., Alvizuri-Pastor, S. E., Contreras-Macazana, R. M., Apolaya-Segura, M., et al. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100311 · Cited by 4

Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19

Parums, D. V. (2021) · Medical Science Monitor · doi:10.12659/msm.935624 · Cited by 4

Temporal dynamics of SARS-CoV-2 antibodies and IgG subclasses following multiple doses and diverse COVID-19 vaccine combinations

Meyer, J., Hoerauf, A. M., Dubiel, A. E., Kovačević, P., Trudić, A., Primorac, D., Hübner, M. P., Adjobimey, T., & Parčina, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1727049 · Cited by 4

Post-acute sequelae of COVID-19 and longitudinal antibody levels in a community-based cohort

Kopplin, N. G., Garcia, A., Reczek, A., Wilkinson, K., Yekkaluri, S., Murphy, C. C., Tiro, J. A., Muthukumar, A. R., Masica, A. L., & Singal, A. G. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291259 · Cited by 4

Are we moving toward ending SARS‐CoV‐2?

Mishra, A., Nayak, D., & Byrareddy, S. N. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27722 · Cited by 3

Impact of Vaccination Policies for COVID-19 Using Hybrid Simulation

Vázquez-Abad, F. J., Dufresne, D., & Park, G.-B. (2022) · Winter Simulation Conference · doi:10.1109/wsc57314.2022.10015370 · Cited by 3

Immunogenicity and Safety of Homologous Booster Doses of CoronaVac COVID-19 Vaccine in Elderly Individuals Aged 60 Years and Older: A Dosing Interval Study — Yunnan Province, China, 2021–2022

Yang, H., Meng, X., Zhuang, T., Wang, C., Yang, Z., Zhu, T., Li, M., Zheng, Y., Wu, Q., Hu, Y., et al. (2023) · China CDC Weekly · doi:10.46234/ccdcw2023.023 · Cited by 4

Comparing the recurrence of audio-vestibular disorders following breakthrough infection of COVID-19 vs. those following vaccine administration

Wang, C., & Young, Y. (2023) · American Journal of Otolaryngology · doi:10.1016/j.amjoto.2023.103970 · Cited by 3

SARS-CoV-2 mRNA Vaccine Elicits Sustained T Cell Responses Against the Omicron Variant in Adolescents

Choi, S.-J., Kim, S.-H., Han, M. S., Yoon, Y., Kim, Y. K., Cho, H., Yun, K. W., Song, S. H., Ahn, B., Kim, Y. K., et al. (2023) · Immune Network · doi:10.4110/in.2023.23.e33 · Cited by 3

Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy

Sieghart, D., Hana, C. A., Dürrschmid, C., Heinz, L. X., Haslacher, H., Zlesak, M., Piccini, G., Manenti, A., Montomoli, E., Jorda, A., et al. (2024) · Journal of Clinical Virology · doi:10.1016/j.jcv.2024.105661 · Cited by 3

Disparities and Outcomes in the First and Second Year of the Pandemic on Events of Acute Myocardial Infarction in Coronavirus Disease 2019 Patients

Dhaliwal, J. S., Sekhon, M., Rajotia, A., Dang, A. K., Singh, P. P., Bilal, M., Sakthivel, H., Ahmed, R., Verma, R., Ramphul, K., et al. (2024) · Medicina · doi:10.3390/medicina60040597 · Cited by 3

Cellular and humoral immunogenicity against SARS-CoV-2 vaccination or infection is associated with the memory phenotype of T- and B-lymphocytes in adult allogeneic hematopoietic cell transplant recipients

Konuma, T., Hamatani‐Asakura, M., Nagai, E., Adachi, E., Kato, S., Isobe, M., Monna‐Oiwa, M., Takahashi, S., Yotsuyanagi, H., & Nannya, Y. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03802-3 · Cited by 3

Association between antibody responses post-vaccination and severe COVID-19 outcomes in Scotland

Macdonald, C., Palmateer, N. E., McAuley, A., Lindsay, L., Hasan, T., Hameed, S. S., Hall, E., Jeffrey, K., Grange, Z., Gousias, P., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00898-w · Cited by 3

A BNT162b2 mRNS-Pfizer–BioNTech-védőoltás hatásosságának és immunogenitásának monitorozása egészségügyben dolgozókon

Rojkovich, B., Németh, D., Török, E., Szabó, B., Pintér, Á., Juhász, I., Weidl, M., Lányi, É., Pável-Szecskó, J., Lázár, I., et al. (2021) · Orvosi Hetilap · doi:10.1556/650.2021.32363 · Cited by 3

SECONDARY INFECTIONS IN THE FAMILY FROM PRIMARY CASES OF COVID-19 BREAKTHROUGH INFECTIONS IN FULLY VACCINATED OR NOT FULLY VACCINATED PEOPLE. TWO DOSES MODESTLY REDUCE FAMILY TRANSMISSION BUT DOES NOT ELIMINATE IT.

Turabián, J. L. (2022) · Journal of SARS-CoV-2 Research · doi:10.36013/sarc-cov-2.v2i.85 · Cited by 3

An Immune Response to Heterologous ChAdOx1/BNT162b2 Vaccination against COVID-19: Evaluation of the anti-RBD Specific IgG Antibodies Titers and Interferon Gamma Release Assay (IGRA) Test Results

Zalewska−Ziob, M., Fus, W., Konka, A., Wystyrk, K., Bochenek, A., Botor, H., Fronczek, M., Zembala-John, J., & Adamek, B. (2022) · Vaccines · doi:10.3390/vaccines10091546 · Cited by 3

Dynamics of Anti-S IgG Antibodies Titers after the Second Dose of COVID-19 Vaccines in the Manual and Craft Worker Population of Qatar

Bansal, D., Atia, H., Badr, M. A., Nour, M., Abdulmajeed, J., Hasan, A., Al-Hajri, N., Ahmed, L., Ibrahim, R., Zamel, R., et al. (2023) · Vaccines · doi:10.3390/vaccines11030496 · Cited by 3

The “identikit” of subject with obesity and COVID-19 vaccine breakthrough

Muscogiuri, G., Barrea, L., Verde, L., Vetrani, C., Savastano, S., & Colao, A. (2022) · EXCLI journal · doi:10.17179/excli2022-4864 · Cited by 5

Evaluation of residual humoral immune response against SARS-CoV-2 by a surrogate virus neutralization test (sVNT) 9 months after BNT162b2 primary vaccination

Pezzati, L., Milazzo, L., Carrozzo, G., Kullmann, C., Oreni, L. M., Beltrami, M., Caronni, S., Lai, A., Caberlotto, L., Ottomano, C., et al. (2023) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2023.03.002 · Cited by 3

Six‐month longitudinal antibody kinetics of mRNA COVID‐19 vaccines

Suresh, L. (2021) · Rheumatology & autoimmunity · doi:10.1002/rai2.12005 · Cited by 2

Comparison of Four Systems for SARS-CoV-2 Antibody at Three Time Points after SARS-CoV-2 Vaccination

Seo, J. D., Nam, M., Lee, T. H., Ahn, Y.-S., Shin, S.-H., Han, H. Y., & Moon, H. (2022) · Diagnostics · doi:10.3390/diagnostics12061349 · Cited by 2

Findings of second multicentric follow-up serosurvey among Health Care Workers in government hospitals

Yadav, A. K., Ghosh, S., Faujdar, D. S., Rajmohan, K., Bhalla, S., Shekhawat, V. S., Jindamwar, P., Dubey, S., Sahai, A., Rakesh, C. R., et al. (2022) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2022.05.013 · Cited by 2

Multiparametric Prediction Models for Coronavirus Disease 2019 Vaccine Selection: Results of a Comparative Population-Based Cohort Study

Sieghart, D., Hana, C. A., Haslacher, H., Perkmann, T., Heinz, L. X., Fedrizzi, C., Anderle, K., Wiedermann, U., Condur, I., Drapalik, S., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac840 · Cited by 2

Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs after Vaccination (DANTE-SIRIO 7) Study in a Large Cohort of Healthcare Workers

Krintus, M., Piasecki, M., Lackowski, P., Buszko, K., Kubica, A., Kosobucka, A., Michalski, P., Pietrzykowski, Ł., Stolarek, W., Wójcik-Kula, A., et al. (2022) · Vaccines · doi:10.3390/vaccines10122125 · Cited by 4

Evaluation of a point of care lateral flow assay for antibody detection following SARS CoV-2 mRNA vaccine series

Lee, W., & Kurien, P. A. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113410 · Cited by 2

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines

Wei, J., Pouwels, K. B., Stoesser, N. E., Matthews, P. C., Diamond, I. D., Studley, R., Rourke, E. D., Cook, D., Bell, J. I., Newton, J. N., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01721-6 · Cited by 248

SARS-CoV-2 anti-spike IgG antibody responses after second dose of ChAdOx1 or BNT162b2 and correlates of protection in the UK general populationPreprint

Wei, J., Pouwels, K. B., Stoesser, N. E., Matthews, P. C., Diamond, I. D., Studley, R., Rourke, E. D., Cook, D., Bell, J. I., Newton, J. N., et al. (2021) · medRxiv · doi:10.1101/2021.09.13.21263487 · Cited by 11

Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster dose

Yavlinsky, A., Beale, S., Nguyen, V. G., Shrotri, M., Byrne, T., Geismar, C., Fragaszy, E., Hoskins, S., Fong, W. L. E., Navaratnam, A. M. D., et al. (2022) · Wellcome Open Research · doi:10.12688/wellcomeopenres.17914.1 · Cited by 10

Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study

Leong, D. P., Zhang, A., Breznik, J. A., Clare, R., Huynh, A., Mushtaha, M., Rangarajan, S., Stacey, H. D., Kim, P. Y., Loeb, M. B., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281673 · Cited by 10

Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose

Sanna, G., Marongiu, A., Firinu, D., Piras, C., Palmas, V., Galdiero, M., Atzori, L., Caria, P., Campagna, M., Perra, A., et al. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01276-x · Cited by 1